Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -2.90 | Insider Own | 7.67% | Shs Outstand | 105.58M | Perf Week | -1.66% |
| Market Cap | 2.12B | Forward P/E | 25.90 | EPS next Y | 0.78 | Insider Trans | 0.00% | Shs Float | 94.61M | Perf Month | 1.93% |
| Enterprise Value | 2.38B | PEG | - | EPS next Q | 0.17 | Inst Own | - | Short Float | 26.02% | Perf Quarter | 14.72% |
| Income | -137.00M | P/S | 1.08 | EPS this Y | 213.82% | Inst Trans | - | Short Ratio | 7.37 | Perf Half Y | 20.78% |
| Sales | 1.97B | P/B | 1.39 | EPS next Y | -76.48% | ROA | -4.29% | Short Interest | 24.62M | Perf YTD | -6.55% |
| Book/sh | 14.47 | P/C | 2.69 | EPS next 5Y | -29.50% | ROE | -9.96% | 52W High | 25.32 -20.58% | Perf Year | 17.95% |
| Cash/sh | 7.46 | P/FCF | - | EPS past 3/5Y | - | ROIC | -5.33% | 52W Low | 14.68 36.99% | Perf 3Y | -83.10% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 33.06% 32.41% | Gross Margin | 58.56% | Volatility | 5.75% 6.89% | Perf 5Y | -75.01% |
| Dividend TTM | - | EV/Sales | 1.21 | EPS Y/Y TTM | -223.93% | Oper. Margin | -7.26% | ATR (14) | 1.36 | Perf 10Y | -29.81% |
| Dividend Ex-Date | - | Quick Ratio | 2.62 | Sales Y/Y TTM | 3.79% | Profit Margin | -6.93% | RSI (14) | 50.23 | Recom | 2.55 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.42 | EPS Q/Q | -102.48% | SMA20 | -3.07% | Beta | 0.36 | Target Price | 23.33 |
| Payout | 0.00% | Debt/Eq | 0.90 | Sales Q/Q | -34.37% | SMA50 | 8.40% | Rel Volume | 1.85 | Prev Close | 20.67 |
| Employees | 835 | LT Debt/Eq | 0.90 | Earnings | Nov 04 | SMA200 | 4.36% | Avg Volume | 3.40M | Price | 20.11 |
| IPO Date | Jun 04, 1997 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -123.01% 9.51% | Net Debt/EBITDA | -32.55 | Volume | 6,292,130 | Change | -2.71% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-27-26 | Reiterated | Morgan Stanley | Equal Weight | $25 |
| Jul-09-26 | Upgrade | Wolfe Research | Peer Perform → Outperform | $27 |
| Jul-09-26 | Reiterated | Piper Sandler | Neutral | $16 → $20 |
| May-15-26 | Reiterated | Evercore ISI | Outperform | $20 → $19 |
| Mar-26-26 | Reiterated | Deutsche Bank | Sell | $12 → $14 |
| Mar-26-26 | Reiterated | Wedbush | Outperform | $29 → $35 |
| Mar-03-26 | Reiterated | Loop Capital Markets | $25 | |
| Mar-03-26 | Reiterated | Jefferies | Buy | $30 |
| Jan-27-26 | Reiterated | Robert W. Baird | $15 → $22 | |
| Dec-09-25 | Initiated | Wedbush | Outperform | $32 |
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,974 | 2,198 | 1,902 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 818 | 882 | 319 | — | — | — | — | — | — | |
| Gross Profit | 1,156 | 1,317 | 1,583 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 437 | 479 | 558 | — | — | — | — | — | — | |
| Research and Development | 789 | 1,522 | 805 | — | — | — | — | — | — | |
| Other Operating Expense | 74 | -26 | 2 | — | — | — | — | — | — | |
| Operating Income | -144 | -658 | 218 | — | — | — | — | — | — | |
| Interest Expense | 60 | 10 | 18 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 70 | -35 | 61 | — | — | — | — | — | — | |
| Net Income Before Taxes | -131 | -702 | 261 | — | — | — | — | — | — | |
| Income Taxes | 6 | 11 | 26 | — | — | — | — | — | — | |
| Consolidated Net Income | -137 | -713 | 235 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -137 | -713 | 235 | — | — | — | — | — | — | |
| Net Income | -137 | -713 | 235 | — | — | — | — | — | — | |
| EPS (Recurring) | -1.44 | -7.13 | 2.47 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.44 | -7.13 | 2.47 | — | — | — | — | — | — | |
| EPS (Diluted) | -2.90 | -7.13 | 2.34 | — | — | — | — | — | — | |
| EBITDA | -15 | -648 | 317 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | 51.96 | — | — | — | — | — | — | |
| Price To Sales Ratio | 1.07 | 1.03 | 6.07 | — | — | — | — | — | — | |
| Gross Margin | 58.56 | 59.92 | 83.23 | — | — | — | — | — | — | |
| Operating Margin | -7.29 | -29.94 | 11.46 | — | — | — | — | — | — | |
| Net Margin | -6.94 | -32.44 | 12.36 | — | — | — | — | — | — | |
| Shares Outstanding | 105 | 105 | 95 | — | — | — | — | — | — | |
| Market Capitalization | 2,112 | 2,260 | 11,551 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Mayo Stephen | Director | Mar 12 '26 | Sale | 17.02 | 7,239 | 123,208 | 1,765 | Mar 13 |
| Estepan Ian Michael | Chief Operating Officer | Mar 01 '26 | Option Exercise | 0.00 | 8,125 | 0 | 208,875 | Mar 03 |
| Rodino-Klapac Louise | President, R&D and Tech Ops | Mar 01 '26 | Option Exercise | 0.00 | 8,125 | 0 | 232,155 | Mar 03 |
| Estepan Ian Michael | Chief Operating Officer | Feb 26 '26 | Option Exercise | 13.71 | 7,450 | 102,140 | 200,750 | Mar 02 |
| Nicaise Claude | Director | Jan 29 '26 | Option Exercise | 13.71 | 10,500 | 143,955 | 38,312 | Jan 29 |
| BEHRENS M KATHLEEN | Director | Jan 27 '26 | Option Exercise | 13.71 | 21,000 | 287,910 | 203,976 | Jan 29 |
| Estepan Ian Michael | Chief Operating Officer | Dec 16 '25 | Sale | 22.31 | 13,187 | 294,202 | 193,300 | Dec 18 |
| Barry Richard | Director | May 16 '25 | Option Exercise | 32.63 | 12,350 | 402,981 | 2,966,667 | May 19 |
| Barry Richard | Director | May 13 '25 | Option Exercise | 19.23 | 20,246 | 389,359 | 2,954,317 | May 15 |
| Nicaise Claude | Director | Mar 12 '25 | Option Exercise | 25.18 | 9,746 | 245,404 | 30,303 | Mar 13 |
| Nicaise Claude | Director | Mar 12 '25 | Sale | 99.64 | 2,491 | 248,203 | 27,812 | Mar 13 |
| Murray Dallan | Chief Customer Officer | Mar 07 '25 | Option Exercise | 0.00 | 5,500 | 0 | 33,659 | Mar 11 |
| Estepan Ian Michael | Chief Financial Officer | Mar 07 '25 | Option Exercise | 0.00 | 5,500 | 0 | 58,277 | Mar 11 |
| Rodino-Klapac Louise | Head of R&D, CSO | Mar 07 '25 | Option Exercise | 0.00 | 5,500 | 0 | 79,818 | Mar 11 |
| Rodino-Klapac Louise | Head of R&D, CSO | Mar 06 '25 | Option Exercise | 0.00 | 17,500 | 0 | 82,822 | Mar 10 |